Loading
Urinary Tract Infections Management / Bladder and Urothelial Cancer Treatments · Journal article
Cancers · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a baseline cross-sectional analysis of 438 treatment-naïve patients with high-risk NMIBC, characterising self-reported health-related quality of life and its associations with physical, emotional, and sexual functioning prior to intravesical BCG ± mitomycin therapy. The study documents that emotional and physical functioning are the strongest independent predictors of global health status in this population, but does not assess treatment efficacy, safety, or longitudinal outcomes.
Baseline cross-sectional analysis from a multicenter randomized controlled trial. Adults diagnosed with high-risk non-muscle invasive bladder cancer, enrolled in the ANZUP BCG + Mitomycin Clinical Trial, prior to initiating intravesical therapy.. Intervention: Baseline assessment only; no intervention applied at the time of data collection presented here.. n = 438. Australian and New Zealand centres (ANZUP trial group); specific number of sites not stated..
Participants were 82% male with mean age 74.9 years; 438 of 501 enrolled completed all questionnaires. Over half reported moderate urinary symptoms that affected quality of life. Emotional functioning (β = 0.411, p < 0.001) and physical functioning (β = 0.355, p < 0.001) were the strongest independent predictors of Global Health Status after adjusting for covariates.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This baseline characterization documents that patients with high-risk NMIBC entering intravesical therapy have significant physical and emotional burden prior to treatment. Clinicians should recognise the baseline psychological and physical constraints in this population and consider supportive interventions, although the data do not yet address whether combined BCG + mitomycin differs from BCG alone or how HRQoL changes during or after treatment.
Baseline cross-sectional descriptive study from an ongoing trial, measuring associations between quality of life and symptom burden in treatment-naïve patients; provides foundational data but no intervention effect, control arm, or outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This baseline characterization documents that patients with high-risk NMIBC entering intravesical therapy have significant physical and emotional burden prior to treatment. Clinicians should recognise the baseline psychological and physical constraints in this population and consider supportive interventions, although the data do not yet address whether combined BCG + mitomycin differs from BCG alone or how HRQoL changes during or after treatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Intravesical therapy is associated with a range of side effects. This study assessed baseline self-reported health-related quality of life (HRQoL) scores and examined associations with clinical and demographic variables, as well as lower urinary symptom severity and bother scores, among individuals diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC) prior to initiating intravesical Bacillus Calmette–Guérin (BCG) therapy, either alone or in combination with Mitomycin. Methods: Baseline data were collected from 501 participants with high-risk NMIBC enrolled in the Australian and New Zealand Urogenital Clinical Trials Group (ANZUP) BCG + Mitomycin Clinical Trial, of whom 438 completed the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C 30, QLQ-NMIBC 24, and the International Prostate Symptom Scoring Tool (IPSS) prior to commencing intravesical treatment. We conducted descriptive and multivariate statistical analyses. We used hierarchical linear regression to examine associations between HRQoL (Global Health Status) and physical functioning, emotional functioning, sexual function, sexual intimacy, and the IPSS total and bother scores. Results: Participants were predominately male (82%), with a mean age of 74.9 years. Over half reported moderate urinary symptoms that affected quality of life. Emotional functioning (β = 0.411, p < 0.001) and physical functioning (β = 0.355, p < 0.001) were the strongest predictors of HRQoL after adjusting for covariates. Conclusions: Individuals diagnosed with high-risk NMIBC report notable physical and emotional concerns prior to commencing intravesical therapy. Targeted interventions may be required to optimise physical and psychological reserve before treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.